60 DEGREES PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
SXTP$0.52-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Balance Sheets
| June 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| ASSETS | ||
| Current Assets: | ||
| Cash | $1,576,602 | $2,142,485 |
| Accounts Receivable | 296,370 | 231,332 |
| Prepaid and Other Assets | 1,458,293 | 4,402,602 |
| Deferred Offering Costs | 5,860 | - |
| Inventory (Note 3) | 426,020 | 466,169 |
| Total Current Assets | 3,763,145 | 7,242,588 |
| Property and Equipment, net (Note 4) | 159,591 | 57,761 |
| Other Assets: | ||
| Right of Use Asset (Note 11) | - | 13,517 |
| Long-Term Prepaid Expense | 154,412 | 242,647 |
| Intangible Assets, net (Note 5) | 250,103 | 227,258 |
| Total Other Assets | 404,515 | 483,422 |
| Total Assets | $4,327,251 | $7,783,771 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts Payable and Accrued Expenses | $643,375 | $506,206 |
| Lease Liability (Note 11) | - | 13,650 |
| SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
| Derivative Liabilities (Note 8) | 567,050 | 2,306,796 |
| Total Current Liabilities: | 1,219,197 | 2,835,424 |
| Long-Term Liabilities: | ||
| SBA EIDL (including accrued interest) (Note 7) | 148,670 | 150,251 |
| Total Long-Term Liabilities | 148,670 | 150,251 |
| Total Liabilities | 1,367,867 | 2,985,675 |
| Commitments and Contingencies (Note 11) | ||
| SHAREHOLDERS’ DEFICIT: | ||
| Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 78,803 and 78,803 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively (Note 6) | 9,858,040 | 9,858,040 |
| Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,017,198 and 484,187 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively(1) (Note 6) | 102 | 48 |
| Additional Paid-in Capital(1) | 29,365,567 | 27,457,335 |
| Accumulated Other Comprehensive Income | 134,804 | 135,561 |
| Accumulated Deficit | (36,323,135) | (32,580,850) |
| 60P Shareholders’ Equity: | 3,035,378 | 4,870,134 |
| Noncontrolling Interest | (75,994) | (72,038) |
| Total Shareholders’ Equity | 2,959,384 | 4,798,096 |
| Total Liabilities and Shareholders’ Equity | $4,327,251 | $7,783,771 |
| (1) | Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024. See Note 12 - Subsequent Events for more information. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.